Diabetes Connections | Type 1 Diabetes

Stacey Simms

Hosted by award-winning broadcaster and journalist Stacey Simms, Diabetes Connections brings a reporter's perspective to the world of diabetes. Since 2015, Stacey has gone beyond the headlines to ask tough questions, break down the latest research and technology, and share honest conversations with the people shaping diabetes care. From industry leaders and researchers to everyday people living with diabetes, Diabetes Connections delivers the news you need, the stories you love, and the questions you want answered. Smart, engaging, and always focused on the diabetes community.

  1. 1d ago

    Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more!

    This week on Diabetes Connections In the News… two new tubeless pumps are cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA  Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns.. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript:    This week on Diabetes Connections In the News… a new tubeless pump is cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA  Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns..   It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We've got a lot to get to, so let's just dive in! Our top story this week: XX Big news – there are now FOUR tubeless insulin pumps FDA cleared. MiniMed Fit and tandem mobi tubeless cleared in the past week – add those to the Beta Bionics Mint and of course, the original, Omnipod. Just yesterday, the FDA cleared the new MiniMed Fit system, which can be worn for up to seven days and holds 300 units of insulin. It has a reusable pump core and a Disposable cartridge – the cannula is built in, so no separate infusion set. Holds 300 units of insulin, with a built-in cannula and reliable adhesive for up to 7 day wear. Reusable pump core — The brains of the pump, this rechargeable part attaches to the disposable cartridge. One charge lasts up to 7 days.The pump uses the same SmartGuard automated insulin delivery technology as MiniMed Flex, adjusting insulin and making corrections every five minutes. The system is fully controlled by smartphone and will be available through pharmacies, with a phased U.S. rollout planned for 2027. https://news.minimed.com/2026-11-16-FDA-Clears-MiniMed-Fit-TM-Worlds-First-and-Only-Tubeless-Insulin-Pump-with-Up-to-Seven-Day-Wear-and-Zero-Interruptions   XX Just a few days ago, Tandem Diabetes Care received clearance clearance for a tubeless version of its Mobi insulin pump, with a wearable cartridge and infusion set designed to last up to seven days. Tandem plans a full U.S. launch in the first half of 2027, with distribution exclusively through pharmacies. This gives people with type 1 another potential option for automated insulin delivery without traditional pump tubing. https://www.drugdeliverybusiness.com/tandems-mobi-pump-wins-fda-clearance-for-7-day-tubeless-wearable-set/ In other Tandem news, the company has issued a recall-related correction affecting more than 80,000 Mobi insulin pumps because of a problem that can trigger false occlusion alarms and interrupt insulin delivery. As of late October, Tandem had received reports of 230 adverse events requiring medical attention or hospitalization, although no deaths had been reported. The issue involves friction inside the pump's motor mechanism, which can cause the device to mistakenly detect a blockage. Tandem says customers can continue using their pumps but should respond promptly to alarms, keep a backup insulin delivery method available, and contact customer support if alarms repeatedly interrupt therapy. The company is investigating the problem and working to prevent it in future devices. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/ XX Just in time for open enrollment, a new free tool aims to make choosing health insurance a little less overwhelming for people with diabetes. The GlucoSense Insurance Navigator compares 2027 Marketplace plans based on what you'll actually spend over the course of a year, not just your monthly premium. It factors in deductibles, insulin, CGMs, pump supplies, doctor visits, and even manufacturer savings cards to estimate your total annual costs. The tool's developers say early users have identified plans that could save them thousands of dollars a year. It's available through the GlucoSense app, although you'll still want to confirm coverage and costs directly with your insurance company before enrolling. Hat Tip to Justin from Diabetech as my source here..   https://www.diabetech.info/p/glucosense-launches-tool-to-help-people-with-diabetes-choose-insurance XX For the first time, the World Health Organization has issued guidelines specifically for diagnosing and managing type 1 diabetes in adults. Released on World Diabetes Day, the recommendations focus on making insulin, blood glucose monitoring, and quality care accessible worldwide, including in countries with limited healthcare resources. The WHO estimates that 9.5 million people worldwide were living with type 1 diabetes in 2025, with another half-million diagnosed that year. The guidelines recommend multiple daily insulin injections, regular glucose monitoring, and the use of CGMs when available. The larger goal is to ensure everyone with type 1 has access to affordable insulin and glucose monitoring by 2030. https://www.who.int/news/item/14-11-2026-who-issues-first-guidelines-on-type-1-diabetes-for-adults XX XX The FDA is requiring new safety warnings on all GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, because of a possible connection to a rare eye condition that can cause sudden vision loss. The condition, called NAION, occurs when blood flow to the optic nerve is reduced and can sometimes cause permanent damage. An analysis of clinical trials found about 6.4 cases per 100,000 patient-years among GLP-1 users, compared with 3.8 among those receiving other treatments or placebos. The FDA says the risk appears very small and researchers have not established that the medications directly cause the condition. Diabetes itself is also a risk factor, making the connection more difficult to untangle. We have an episode coming up next week where we'll talk a bit more about his. https://www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html A new study of more than 8,400 adults with type 1 diabetes in the Veterans Health Administration found that people who started using CGMs had a lower risk of death over the following four years. The estimated reduction in mortality risk was about 16 percent at four years, with potentially greater benefits for adults over 65 and those not using insulin pumps. Researchers emphasize that this was an observational study, so it doesn't prove CGMs directly caused the improvement. Still, the findings add another compelling argument for expanding access to diabetes technology. https://www.emjreviews.com/en-us/amj/diabetes/abstract/continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-patients-with-type-1-diabetes-a-target-trial-emulation-study-using-national-healthcare-data-j04126/ XX   XX Researchers are getting closer to understanding a long-standing mystery in type 1 diabetes: why children whose mothers have type 1 are about half as likely to develop the condition as children whose fathers have it. A University of Colorado study followed nearly 7,000 children at increased genetic risk and found that inherited genes don't explain the difference. The protective effect appears to happen early in life, particularly before age six, when the immune system may begin attacking insulin-producing cells. Researchers also found no evidence that pregnancy loss explains the difference, as some had previously suggested. The next step is figuring out what biological process might be providing that protection and whether it could eventually help prevent type 1 diabetes. https://medicalxpress.com/news/2026-11-genetic-maternal-effect-diabetes.html XX Researchers in Israel are reporting promising early results from an experimental treatment for LADA, sometimes called type 1.5 diabetes. Scientists at Bar-Ilan University combined three drugs — GABA, sitagliptin, and omeprazole — and found that about 30 percent of treated mice returned to normal blood sugar levels without insulin, even after treatment ended. The researchers also identified blood markers that could predict which mice would respond, potentially opening the door to more personalized treatments. LADA is a form of autoimmune diabetes that typically develops more slowly in adults. This research is still in mice, not humans, but it offers an interesting new direction for treating autoimmune diabetes. https://www.timesofisrael.com/israeli-scientists-use-common-drugs-to-cure-30-of-mice-with-type-1-5-diabetes/ XX A fully automated artificial pancreas that delivers both insulin and glucagon is showing mixed results in a new year-long study involving more than 240 adults with type 1 diabetes. Unlike current hybrid closed-loop pumps, this system doesn't require users to count carbs, announce meals, or make adjustments for exercise. Researchers found it improved time in range by nearly two hours a day compared with multiple daily injections, but offered no

  2. 5d ago ·  Bonus

    Finding Diabetes Joy: How Poetry Helped Ephraim Navigate a T1D Diagnosis

    In this bonus episode of Diabetes Connections, meet Ephraim Sommers, an English professor and poet diagnosed with LADA (a slower-developing form of type 1 diabetes) in his early 40s. Even though his father has type 1, Ephraim wasn't prepared for the fear, anxiety, and mental load of managing diabetes himself. So he turned to poetry. Every weekday, he sat in a coffee shop and wrote about gratitude. Those poems became Diabetic Gumdrops, a new book about finding joy while living with diabetes. We talk about shifting from fear to gratitude, advocating for yourself, and why poetry might help even if you haven't read a poem since high school. Plus, Ephraim lives right here in the Charlotte area! We had a great time talking about the local T1D community and how important connection can be. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

  3. Nov 10

    Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman

    This week on Diabetes Connections - looking into a very old vaccine to get new results for people with type 1. Dr. Denise Faustman's research into the BCG vaccine has been making headlines for a long time, and she's now sharing new results from her clinical trials, including some pretty remarkable claims about A1C, insulin use, and time in range. Now, I know some of you may be surprised that I'm having Dr. Faustman on the show. She's a very controversial figure in the diabetes research world, and her work has sparked plenty of debate and skepticism over the years. We're not ignoring any of that. In fact, we talk directly about the controversy, why she believes her research has faced resistance, and what it would take for BCG to become a widely accepted treatment. This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider. More about Dr. Faustman's work here More about the controversy and history here Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

  4. Nov 3

    In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more

    This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. And it's diabetes awareness momth! It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy. We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month. Okay.. our top story this week: XX Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign. https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. Statement from Dexcom: We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information.     These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly.     Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time.     We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices.   XX Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter. Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned. Source: Drug Delivery Business News XX In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications.  Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk. Source: Medscape XX New research suggests that widely used tools for predicting heart disease risk may significantly underestimate that risk in people with type 1 diabetes. Researchers analyzed decades of data from more than 1,300 participants in the long-running DCCT/EDIC study and found that actual cardiovascular events occurred more frequently than several standard risk calculators predicted. Adding a coronary artery calcium scan, which looks for calcium buildup in the arteries, improved predictions somewhat, but not dramatically. The findings, presented at the 2026 European Association for the Study of Diabetes meeting, highlight the need for better heart disease risk assessment tools designed specifically for people with type 1. Source: Medscape XX Eli Lilly is reporting impressive results for retatrutide, its experimental drug that targets three different hormone receptors, including GLP-1. In a Phase 3 study involving nearly 1,300 adults with type 2 diabetes, retatrutide lowered A1C by 2.2 percentage points, compared with 1.8 points for Ozempic. Participants taking retatrutide also lost an average of 44 to 47 pounds, roughly twice as much as those taking Ozempic. Side effects, including diarrhea and unusual skin sensations, were more common with retatrutide. The drug is not yet approved, and Lilly plans to seek FDA approval in early 2027. Source: BioSpace XX It's official: MiniMed is now a fully independent company, completing its separation from longtime parent company Medtronic. MiniMed went public earlier this year, and Medtronic has now exchanged its remaining shares, ending its ownership stake in the diabetes technology business. MiniMed CEO Que Dallara says the independence gives the company more freedom to make decisions and advance diabetes care. The company is still working to separate some of its technology services from Medtronic, a process expected to continue into 2027. Source: MedTech Dive XX Still to come, an implant designed to remove excess glucose without medication, help for younger adults with type 2, and type 1 hits the streets of new York.. right after this. XX Scientists in Switzerland and France have developed an experimental implant that removes excess glucose from the blood without using insulin or other diabetes medications. The tiny wireless device works with a continuous glucose monitor and uses an electrical reaction to convert glucose into a substance called gluconate, which is then cleared by the kidneys. In mice with type 2 diabetes and obesity, the device lowered blood sugar and reduced body weight by about 10% over six weeks. Researchers say the technology could eventually offer a new approach to treating type 2 diabetes, but it's still in the very early stages, with no human trials yet. Source: Live Science XX A new study suggests that an intensive diet and exercise program can help some younger adults with type 2 diabetes achieve remission in just six months. Researchers followed 96 adults under age 45 and found that 54% of those in a medically supervised program achieved remission, compared with just 4% receiving standard care. The program included a very low-calorie diet of 800 to 900 calories per day during its initial phase, along with structured aerobic and strength training. Remission means blood sugar returns below the diabetes threshold without glucose-lowering medication, but it doesn't necessarily mean a permanent cure. These findings apply to type 2 diabetes, not type 1, and the intensive program was conducted under medical supervision. Source: ScienceDaily XX Two big shoutouts for type 1 diabetes and sports. Major congrats to everyone who completed or even attempted the NYC Marathon – I'm in awe of how much training you've all put in. What an amazing accomplishment. And of course, I know some time has gone by, but one more mention of Garrett Mitchell from the World Series champion Milwakee Brewers.   A big week for people with type 1 diabetes in sports! Congratulations to everyone with T1D who took on the New York City Marathon, and a special shoutout to Milwaukee Brewers outfielder Garrett Mitchell. We'll have more on Mitchell and his story coming up. XX I anticipate a lot of diabetes month news and campaigns and I'll share on social if I find them interesting and actionable. I don't really do much that's different – every month is diabetes awareness month around here. I do think it's a wonderful time to get information out to the non-diabetes community. Project Blue Novmeber always does a great job all month long if you're looking to shrae iformatoin via social. That's it for in the news! This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely

  5. Oct 27

    What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill

    What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes. I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care. We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it. This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider. More about the Congress here Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

  6. Oct 20

    In the News.. Dexcom controversy, New T1D research, and a World Series moment to remember!

    This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response  New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series! Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up. Off to Seattle in a couple of days for MNO.. Okay.. our top story this week: XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms. The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features. Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here.. (clip) I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration. I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update. XX Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.   XX SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective. https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html XX Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes. https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe XX A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1 diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10   XX A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy. T1d pregnancy and me study team, we did an episode on this. XX A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary. https://www.sciencedaily.com/releases/2026/10/261017230031.htm XX Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).   From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.   "Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shapi

  7. Oct 13

    Sernova + Seraxis: A New Partnership in the Race for a T1D Cure with CEOs Johnathan Rigby and Dr. Will Rust

    A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes. So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1? I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 -  and Will Rust about the science, the challenges, and why they believe this combination could be a game changer. Our past episodes with Sernova here This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

4.7
out of 5
220 Ratings

About

Hosted by award-winning broadcaster and journalist Stacey Simms, Diabetes Connections brings a reporter's perspective to the world of diabetes. Since 2015, Stacey has gone beyond the headlines to ask tough questions, break down the latest research and technology, and share honest conversations with the people shaping diabetes care. From industry leaders and researchers to everyday people living with diabetes, Diabetes Connections delivers the news you need, the stories you love, and the questions you want answered. Smart, engaging, and always focused on the diabetes community.

You Might Also Like